Avadel Pharmaceuticals plc (AVDL) EPS Estimated At $-0.30; 1 Analysts Are Bullish Aimia Inc. (TSE:AIM) Last Week

April 19, 2018 - By Linda Rogers

Aimia Inc. (TSE:AIM) Logo

Analysts expect Avadel Pharmaceuticals plc (NASDAQ:AVDL) to report $-0.30 EPS on May, 8.They anticipate $0.56 EPS change or 215.38% from last quarter’s $0.26 EPS. After having $-0.28 EPS previously, Avadel Pharmaceuticals plc’s analysts see 7.14% EPS growth. The stock decreased 1.24% or $0.09 during the last trading session, reaching $7.19. About 41,006 shares traded. Avadel Pharmaceuticals plc (NASDAQ:AVDL) has declined 26.36% since April 19, 2017 and is downtrending. It has underperformed by 37.91% the S&P500.

Among 6 analysts covering Aimia (TSE:AIM), 1 have Buy rating, 1 Sell and 4 Hold. Therefore 17% are positive. Aimia had 25 analyst reports since August 6, 2015 according to SRatingsIntel. The stock of Aimia Inc. (TSE:AIM) earned “Outperform” rating by Raymond James on Friday, February 10. The rating was maintained by Raymond James on Friday, February 17 with “Outperform”. The rating was maintained by RBC Capital Markets with “Sector Perform” on Wednesday, November 9. The firm earned “Sector Perform” rating on Tuesday, February 21 by RBC Capital Markets. IBC upgraded Aimia Inc. (TSE:AIM) on Tuesday, January 10 to “Underperform” rating. The stock of Aimia Inc. (TSE:AIM) earned “Hold” rating by TD Securities on Wednesday, November 2. See Aimia Inc. (TSE:AIM) latest ratings:

Avadel Pharmaceuticals PLC identifies, develops, and commercializes pharmaceutical products for primary care and sterile injectable markets in the United States, France, and Ireland. The company has market cap of $272.88 million. The company's owns and develops drug delivery platforms, such as Micropump, a microparticulate system that allows the development of modified and/or controlled release of solid and oral dosage formulations of drugs; LiquiTime, which allows development of modified/controlled release liquid suspension formulations; Trigger Lock that allows development of abuse-deterrent modified/controlled release formulations of narcotic/opioid analgesics and other drugs susceptible to abuse; and Medusa, a hydrogel depot technology that allows the development of extended/modified release of injectable dosage formulations of drugs. It has a 4.41 P/E ratio. The Company’s lead products include Bloxiverz, a drug used in the operating room for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery; Vazculep, a phenylephrine hydrochloride injection used to treat hypotension; and Akovaz, an ephedrine sulfate injection.

Aimia Inc., through its subsidiaries, operates as a data-driven marketing and loyalty analytics firm worldwide. The company has market cap of $258.92 million. It operates through Americas Coalitions, International Coalitions, and Global Loyalty Solutions divisions. It currently has negative earnings. The firm owns and operates the Aeroplan Program, a coalition loyalty program in Canada, as well as non-platform based loyalty services business; the Nectar UK and Air Miles Middle East coalition loyalty programs; and Travel Club, a coalition loyalty program in Spain.

The stock increased 0.59% or $0.01 during the last trading session, reaching $1.7. About 79,670 shares traded. Aimia Inc. (TSE:AIM) has 0.00% since April 19, 2017 and is . It has underperformed by 11.55% the S&P500.

Avadel Pharmaceuticals plc (NASDAQ:AVDL) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.